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As part of the State Targeted Response to the opioid epidemic, California has adopted the Hub and
Spoke model to expand access to medications for opioid use disorder, particularly buprenorphine,
throughout the state. By aligning opioid treatment programs as hubs with primary care, officebased practitioners, and other health care settings as spokes, a broader treatment model can reach
more people with opioid use disorder, improve access to medications for opioid f specific activities
and anticipated impact of the implementation plan in California’s Hub and Spoke system. Training
and technical assistance are designed to: increase the number and specific activities and
anticipated impact of the implementation plan in California’s Hub and Spoke system. Training and
technical assistance are designed to: increase the number and capacity of waivered prescribers;
enhance skills of prescribers and multidisciplinary teams; and create systems change. Activities
include buprenorphine waiver trainings and provider support, a practice facilitator program,
Project ECHO sessions, webinars, clinical skills trainings, and regional learning collaboratives.
This overview highlights the steps California is taking to build treatment capacity to address the
opioid epidemic.
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1.

Introduction

Author Manuscript

To address the overdose crisis and opioid epidemic in California, the California Department
of Health Care Services (DHCS) prioritized expansion of access to medication treatment for
opioid use disorders (MOUD)1. In order to reach 20,000 new patients on MOUD over a twoyear period, DHCS selected the Hub and Spoke (H&S) model, developed in Vermont
(Simpatico, 2015), to create a treatment system that expands access to care for opioid use
disorders (OUD). California allocated nearly half of the federal funds provided in its State
Targeted Response (STR) grant (2017-2020; approximately $43 million dollars) to build its
Hub and Spoke system and expand treatment capacity throughout the state. This paper
describes California’s adaptation and implementation of the Hub and Spoke model and
elements of the implementation support for the project.

Author Manuscript

Like the Vermont H&S system, California developed collaborative regional networks of
clinical services for treatment-seeking opioid users that expand service capacity, increase
access to care, and promote patient placement in the most effective type and intensity of
MOUD treatment. The regional networks have “hub” clinics, mainly opioid treatment
programs (OTPs) that prescribe methadone, buprenorphine, and injectable naltrexone, to
patients who need the high level of structure provided in these treatment settings. The OTPs
then contract with a geographically distributed number of “spoke” clinics, mainly primary
care, but also behavioral health and substance use disorder programs, where patients can
receive office-based opioid treatment (OBOT) with buprenorphine and injectable naltrexone.
The implementation activities focused on expanding access to MOUD described here have
the aims of: increasing the number of waivered prescribers in the state; increasing the
capacity and confidence of those prescribers; and enabling systems change to implement
buprenorphine treatment across the treatment system.
1.1

The Hub and Spoke System.

Author Manuscript

Only 8% of people with a substance use disorder seek treatment at a publicly-funded
substance use treatment program (SAMHSA, 2018), but many more have contact with a
primary care provider. By creating an integrated network of OTP and OBOT settings, the
H&S model allows more patients to access treatment wherever they enter, creating a “no
wrong door” system of care. The H&S model can also increase provider capacity to treat
substance use disorders (Brooklyn and Sigmon, 2017)While primary care physicians do not
typically specialize in addiction medicine, so the H&S model provides a structure for
treatment teams to provide medications for opioid use disorders like they do for other
chronic illnesses. By creating a network of shared expertise, the H&S model can help these
1Throughout this manuscript we use both the term medically-assisted treatment (MAT) which has been widely used and the term
medication treatment for opioid use disorder (MOUD). MOUD is the preferred term for the authors as we believe this term more
accurately reflects the nature of these pharmacotherapies.
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providers begin prescribing medications like buprenorphine in OBOT settings. California
has applied knowledge derived from Vermont in designing and developing its own H&S
network.

Author Manuscript

The implementation of the H&S concept in the expansive and geographically diverse State
of California (California is approximately 17 times larger than Vermont and its population
approximately 63 times greater) requires strategies that can accommodate its much larger
size. California has 58 counties, each with a different configuration of healthcare and opioid
treatment services. Some counties are urban with dense populations and others are rural or
frontier, with large distances creating access obstacles to care for people with substance use
disorders and other chronic conditions. Because of the greater diversity in California, hubs
were encouraged to create systems that best meet the needs of their communities. For
example, in more rural areas without access to transportation and few providers nearby, the
hubs could use funds to help spokes set up telehealth services, pay for a provider to attend a
waiver training, or provide salary support for behavioral health or nursing services that are
not typically funded by Medi-Cal (California’s Medicaid program).

Author Manuscript

DHCS funded proposals to establish 18 H&S networks in California in June 2017. These
networks provide services in 38 counties, representing 70.6% of the geographic area of
California and 70.0% of the state’s population. The 18 hubs represent 17 OTPs and one
Federally Qualified Health Center (FQHC) with a MOUD program. In their proposals, each
hub identified five or more spokes who either already had a MOUD program or were
interested in developing one. Spokes could include FQHCs, other mental health and
substance use disorder programs, and private practitioners with a DATA 2000 waivered to
prescribe buprenorphine. The one FQHC that serves as a Hub delivers MOUD services in a
county without an OTP. They contract with an OTP in a neighboring county to provide
methadone and more intensive levels of care as needed, while the process was underway for
an OTP to open in that county.
Figure 1 shows the geography of the 18 H&S networks across six regions, mainly defined by
geography and projected number of spokes. In the RFP, the priority for funding was to cover
parts of California with the highest overdose rates, which overlap with the areas of
California with the fewest services for OUD, most of which are located in the rural north. As
illustrated in Figure 1, the H&S networks serve most of the very rural counties of Northern
California, the Sierras and the vast desert counties in Southeastern California, in addition to
the urban counties of San Francisco, Los Angeles, San Diego and others.

2.
Author Manuscript

2.1.

Methods.
The California H&S project implementation plan
The training and implementation grant for the CA H&S program was awarded to the
Integrated Substance Abuse Programs (ISAP) training department at the University of
California at Los Angeles (UCLA). This experienced addiction service development and
training team created an implementation plan to support the H&S efforts. The team included
staff from UCLA (including the SAMHSA-funded Pacific Southwest Addiction Technology
Transfer Center [PSATTC]), Stanford University faculty, members of the California Society
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of Addiction Medicine (CSAM), and informal consultants from the California Health Care
Foundation (CHCF) and California Primary Care Association (CPCA), with active
involvement from the funder, DHCS.

Author Manuscript

The implementation plan includes a set of evidence-based dissemination and training
activities meant to improve treatment capacity in order to contain and reduce the opioid
overdose death rate in California. With the H&S framework as the conceptual model for the
organization of treatment services, the plan promotes the expansion of MOUD access by
increasing California OTPs’ capacity to treat patients with buprenorphine and expanding the
use of buprenorphine in primary care and other non-OTP settings. Given California’s large
and complex geography and scope of provider reach, the plan includes a mixture of inperson and distance learning opportunities, group learning events, and one-one-one
mentorship. All activities are designed to address the state’s goals of expanding the
availability of MOUD, reducing opioid overdose rates, and reducing unmet treatment needs.
The implementation activities can be organized into three categories: increasing the number
and capacity of waivered prescribers; enhancing skills of prescribers and their treatment
teams; and facilitating systems change to implement buprenorphine treatment across the
treatment system. A different team at UCLA was awarded a contract to evaluate the extent to
which the goals of the California STR effort produce its intended effects (Darfler, Urada,
and Sandoval, under review).
2.2.

Increasing the Number and Capacity of Waivered Prescribers.

Author Manuscript

To deliver MOUD (specifically buprenorphine) in primary care settings, physicians (MDs
and DOs), Nurse Practitioners (NP), and Physicians Assistants (PA) need to complete a
required 8-hour (physicians) or 24-hour (NPs and PAs) course to qualify to prescribe
buprenorphine by obtaining Drug Addiction Treatment Act of 2000 (DATA 2000) waiver.
One major difference between the approach to H&S implementation in Vermont and
California relates to the availability of buprenorphine prescribers. In Vermont there is one
prescriber for every 4,000 people (640,000/160), while in California, there is one for every
11,500 (40,000,000/3500; National Technical Information Service, 2018). As such, one of
the priorities of the CA H&S implementation has been to develop a larger cadre of
buprenorphine prescribers. Once providers are waivered, they then need more support to
promote active and expanded involvement in prescribing buprenorphine for OUD (Huhn et
al., 2017; Hutchinson et al., 2014).

Author Manuscript

2.2.1. Buprenorphine Waiver Trainings—In 2018, UCLA coordinated nine waiver
trainings throughout the state, with a focus on rural areas. Approved faculty teach the
Providers Clinical Support System (PCSS) training (www.pcssnow.org). While there are a
variety of training formats for the waiver training, e.g., 8 hours online, 8 hours in-person,
half in-person, half online), UCLA arranged for the “Half and Half’ curriculum to provide
the first half as a live training with an expert trainer. Providers received information about
waiver trainings in a variety of ways, including direct outreach by hubs to their spoke
providers, collaboration with medical centers to promote the training, announcements
through the H&S listserve, and a list of interested providers compiled over the course of the
project. From these nine training events, 132 providers received the training and instructions

J Subst Abuse Treat. Author manuscript; available in PMC 2021 January 01.

Miele et al.

Page 5

Author Manuscript

on how to complete the online portion to become eligible for their x-waivers. Other waiver
training efforts outside of H&S are taking place throughout the state, and the evaluation will
track the total growth of waivered prescribers through publicly available databases.

Author Manuscript

2.2.2. The Medical Education Research Fellowships (MERF) for the
Treatment of Addiction (MATES)—MERF-MATES is a sister-program to CSAM that
focuses on medical education on all aspects of addiction. In the treatment of OUD, the
program provides education and support for waivered providers to build their skills in
prescribing buprenorphine and become more confident and competent to treat people with
substance use disorders. MERF Scholars receive scholarships to attend the CSAM annual
meeting and participate in a special educational track focused on treating OUD, learning
from faculty and peers. During and after the conference, MERF scholars meet with a mentor
who assists them in learning the basic steps in treating patients with MOUD and supporting
their use of buprenorphine in their clinical practice. MERF will evaluate the impact of the
program in a variety of ways. More at merfweb.org.

Author Manuscript

2.2.3. Prescriber Facilitator Program.—In the creation and operation of the H&S
system in Vermont, the medical directors of the hubs in Vermont played a critical role. In
Vermont, hub medical directors (overseeing services in 6 of the 7 hubs) were all active
leaders in the H&S development process. These doctors prescribed methadone and
buprenorphine in the hubs and were active “champions” for buprenorphine in primary care
settings. They led community training sessions with new prescribers and were available to
provide mentoring for doctors in spokes on the use of buprenorphine. In Vermont, most hub
physicians view themselves as experts in addiction medicine with a responsibility for
helping to build overall MOUD capacity in Vermont. They do not see their role as limited to
being the prescriber in the OTP setting.
In California OTPs, the medical directors have a more limited scope of responsibility. Most
are experienced practitioners on the use of methadone for OUD. At the time of the initiation
of the California H&S, many of the hub doctors had little, if any experience with
buprenorphine and no experience in providing mentoring to prescribers outside of their
OTP/hub settings. Unlike Vermont, the medical personnel in most of the hubs in California
were not able to help the spoke doctors become proficient with the use of buprenorphine or
with other aspects of MOUD treatment.

Author Manuscript

As the California H&S system progressed, it became clear that many spokes faced
challenges in implementing MOUD expansion among new or beginning x-waivered
providers, in part due to the gap of medical expertise and mentorship that was present in the
Vermont model. To address this need, an “Implementation Facilitation” model based on the
work of the Veterans Health Administration was used to engage experienced waivered
physicians to mentor, coach, and advise the new and prospective spoke providers (Ritchie et
al., 2017).
The Implementation Facilitation model stems from an identified need to assist and
encourage providers to use a new practice (in this case MOUD) and, through the
development of interpersonal relationships, addresses challenges in adoption through
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interactive problem solving and support (Stetler et al., 2006). Implementation facilitation has
been shown to have a positive impact on organizations that, like the California H&S system,
face significant challenges in implementation of evidence-based practice in clinical settings
(Ritchie, Parker, Edlund, & Kirchner, 2017; Kirchner et al., 2014). The H&S project is using
this model to provide new spoke doctors with this support in a Prescriber Facilitator
program.

Author Manuscript

A first step in developing the prescriber facilitator program was to identify a cohort of
experienced physicians who actively prescribe buprenorphine in primary care settings
throughout California. The UCLA/Stanford team, along with advisors, identified prescribers
in all geographic areas of the state that had a hub. Candidates were experts in the use of
buprenorphine and have an interest in teaching other prescribers and championing the
development of MOUD use in primary care settings. Each hub works with a Prescriber
Facilitator, a MOUD champion in the community experienced in providing MOUD in
primary care and trained on the facilitation model. The facilitators work with hub
administrators to perform implementation activities including planning, leading, managing
and sustaining change, and monitoring progress (Ritchie et al, 2015; Ritchie et al, 2017;
Dogherty, Harrison, Graham, & Keeping-Burke, 2014). Facilitator activities include
mentoring, coaching, and support of new or perspective spoke providers. Facilitators meet
with spoke doctors, as “dyads,” virtually or face to face, field phone calls, and provide
consultation as needed. Introductory phone calls and webinars provide a review of
expectations and the model. Since the facilitator program launch in September of 2018, two
webinars have occurred in addition to meetings with each dyad completed at program onset.
The two webinars consisted of initial training on and introduction to practice facilitation for
the dyads and an internal call between the practice facilitators. The immediate next steps for
the program will include creation of an interactive platform for facilitator exchange and a
third convening of all dyads.

Author Manuscript

The facilitator program is intended to increase the number of active buprenorphine
prescribers within the spokes of the 18 H&S networks. It is anticipated that the H&S
networks with the most active facilitators will see the largest increase in new prescriber
activity and patients in treatment with buprenorphine. Qualitative interviews planned in the
final year of the project will query spoke doctors on their views of the usefulness of the
prescriber facilitator program.
2.3.

Enhancing skills of prescribers and their treatment teams.

Author Manuscript

In addition to increasing the number of waivered prescribers, along with their prescribing
activity, implementation efforts include enhancing the skills of other members of the
treatment team, including nurses, behavioral health specialists, case workers, administrators
and other professionals involved in developing MOUD programs and delivering services.
The implementation team has designed a variety of learning activities that support this
process, including Project ECHO, Clinical Skills trainings, and community-wide MOUD
webinars.
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2.3.1. Project ECHO—Project ECHO (Enhancing Community Health Care Outcomes)
uses a web-based, video conferencing platform to provide a “lifelong learning and guided
practice model that revolutionizes medical education and exponentially increases workforce
capacity to provide best-practice specialty care and reduce health disparities.” (Project
ECHO, 2019). Expert teams lead virtual ECHO clinics providing primary care doctors,
nurses, and other clinicians an opportunity to learn how to provide evidence-based specialty
care in their own communities. A number of studies have investigated the impact of Project
ECHO on pain management and opioid prescription rates as well as management of
substance use disorders generally (Carey, Frank, Kerns, Ho & Kirsh, 2016; Katzman et al.,
2014; Chaple et al., 2018). Currently, a limited number of studies have investigated the
impact of Project ECHO on opioid use disorder patient-level outcomes and/or buprenorphine
prescriptions (Komaraomy et al., 2016; Korthuis et al., 2017).

Author Manuscript

The CA H&SS project offers monthly 1-hour, web-based sessions, called MAT ECHO
Clinics, led by medical and addiction experts with a curriculum designed to meet the needs
of the CA H&SS programs and providers. The topics and curricula were developed by
experts at the ECHO Institute at the University of New Mexico and adapted by H&SS staff
to meet the needs of California providers (Project ECHO, 2019). CEs and CMEs are
available for certified and licensed participants. The MAT ECHO topics have included:
Introduction to Project ECHO® and to Opioid Use Disorder; Treatment of Opioid Use
Disorders; Risk Reduction: Overdose Prevention and Management of Prescribed Opioids;
Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes; Medication Assisted
Treatment (MAT) and Pregnancy; MOUD and Polysubstance Use; Nurse Care Model;
Talking to Patients about MOUD; Adverse Childhood Experiences and SUDs.

Author Manuscript

The primary role of Project ECHO within the California H&S implementation plan is to
provide a venue for waivered providers and the treatment team to learn evidence-based
practices and have an opportunity to present and get feedback on clinical cases. Cases are
presented by prescribers, nurses, and mental health providers, mainly from the spokes. As of
May 2019, nine sessions have been offered, and the reach of these virtual case conferences
has been 30-50 people per session.

Author Manuscript

2.3.2. Webinars and Clinical Skills Trainings—The knowledge and skills needed to
provide treatment to individuals with OUD are substantial. It is beyond the scope of this
implementation project to provide comprehensive knowledge and skills training to all the
clinical staff working within the California H&S project. However, with input from H&S
clinicians and advisors, the implementation team prioritized a set of topics perceived to be of
greatest importance to the success of the treatment efforts in the H&S service delivery
system. The funder was also interested in reaching providers outside the H&S network, so
the implementation plan includes a series of community-wide webinars open to anyone
interested. Face to face clinical skills training sessions are offered twice per year to enable
participants to learn and practice important skills in a more in-depth training experience.
2.3.2.1. Community-Wide Webinars: Every quarter, the project team delivers a webinar
that is open to the public to provide evidence-based education on various aspects of opioid
use disorder to anyone interested in the topic. This allows those in the H&S as well as
J Subst Abuse Treat. Author manuscript; available in PMC 2021 January 01.

Miele et al.

Page 8

Author Manuscript

interested individuals outside the H&S system to engage in learning opportunities that may
facilitate MOUD expansion in other areas of the state. Potential participants receive
announcements about these sessions through the H&S communication channels, as well as
the PSWATTC List serve and distribution by affiliate organizations, such as CSAM, CPCA,
and CHCF. Topics for these sessions have included: MOUD 101: An Overview of MOUD;
Providing Medications for Opioid Use Disorder in Integrated Settings; Coordinating Care
with a MOUD Team (featuring experts from a Vermont MOUD Team); Stigma and MOUD;
Stimulants, Opioid Use Disorders and Patients on MOUD.

Author Manuscript

Sessions have been developed to include a variety of stakeholder perspectives. For example,
the Stigma and MOUD webinar included a presentation by a family medicine physician who
talked about the stigma she has seen working with pregnant patients with opioid use
disorders. That session also included a consumer in long-term recovery from Opioid Use
Disorder who discussed how stigma impacted his ability to start and maintain treatment. As
of May 2019, 60-100 people have attended each of the six sessions.

Author Manuscript

2.3.2.2. Clinical Skills Training: Bi-annual clinical skills trainings are provided for H&S
personnel in multiple sites throughout the state. These sessions are designed to: 1) Review
the most significant clinical challenges faced in the specified region. 2) Present evidence
based/best practices known to be useful to address these challenges, and 3) Provide practice
and role playing of clinical skills to promote use of the techniques presented. The first
training focused on teaching motivational interviewing (MI) skills to all levels of personnel
working in the H&S system. In year 2, the clinical skills trainings were designed to address
two treatment challenges that continued to arise in Learning Collaboratives: how to address
pain in patients on MOUD; and how to treat pregnant women with OUD. These evidencebased trainings were designed to include a presentation on the science of treating patients
with OUD; a presentation on the clinical practice of applying evidence-based care; and a
question and answer session. Three trainings on Pain and OUD and five trainings on
Pregnancy and OUD were offered in different geographic regions throughout the state with
attendance of 25-50 participants in each session.
2.4.

Facilitating Systems Change.
Implementing a successful MOUD program requires a number of systems and attitudinal
changes. An integrated care model where OTPs, primary care providers, mental health
programs, and others work together is a shift from the more typical “siloed” models of care
available in health care systems. The implementation plan includes Learning Collaboratives
to address those systems changes.

Author Manuscript

2.4.1. Learning Collaboratives—Learning collaboratives (LCs) gather stakeholders
together as an established strategy for reducing practice variation, caring for complex
patients, and implementing relevant practice guidelines in healthcare settings (Institute for
Healthcare Improvement, 2003). Learning collaboratives increase engagement in and
completion of clinical training programs (Nadeem et al, 2016), increase positive attitudes
toward empirically based treatment, and sustainability of evidence-based clinical practice
over time (Haine-Schlagel, Brookman-Frazee, Janis, & Gordon, 2013). The LC was a core
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component of the Vermont H&S system (Nordstrom et al., 2016). Based upon the increases
in expanding MOUD access (Brooklyn & Sigmon, 2017) and positive clinical outcomes
documented in Vermont (Rawson et al., 2019), the LC strategy is a central element in the
California implementation plan.

Author Manuscript

In view of the large distances of California and the size of the project (18 hubs and over 200
spokes), the 18 H&S networks were grouped into six regional LCs, mainly organized by
geography, to enable greater in-person participation and relevance. The LCs provide a venue
for prescribers, other clinicians, and administrators from the hubs and spokes to learn
important topics related to prescribing buprenorphine and provide opportunities for
interactive problem solving. OTP/hub personnel use this opportunity to meet and become
more familiar with the personnel and processes in their spoke networks. Because the
“cultures” in OTPs and primary care settings are so different, it is a useful setting for all
stakeholders to learn more about the procedures and operational issues of the spokes and
vice versa. Refer to Figure 1, above, for the map of the six LC regions, by color.

Author Manuscript

LCs are held quarterly, and each session includes: A CME topic presentation; a “case study,”
which can be clinical or administrative; and a presentation of quality improvement measures
based on specified data collected from the hubs and spokes. Each group has a facilitator and
includes a presentation by a local practice expert. The implementation team, with input from
H&S administrators and clinicians and consumers and an informal advisory group, created
the agenda of topics, including: Introduction to the Learning Collaborative: Building a
System of Care for Persons with OUD; Talking to Patients about MOUD; Effective
Implementation of the Hub and Spoke Model: Prescribers and MAT Teams; Best Practices
in Interdisciplinary Care; MOUD and Comorbid Substance Use; Best Practices in Treatment
Retention. Twenty-five to 50 participants attend each session in each of the six regions.

3.

Discussion and Future Directions

Author Manuscript

California has developed a Hub and Spoke system of care intended to increase access to lifesaving medications that reduce overdose deaths. The efforts in California and other states
addressing the opioid epidemic through these and other projects funded by the federal State
Targeted Response and State Opioid Response grants will result in a greater understanding
of how to best address the opioid crisis. The Hub and Spoke model offers a significant
change of practice in the health care system. Ongoing evaluation of the programmatic
elements and implementation activities of these projects will highlight which aspects are
most important to these efforts, especially as integrated treatment approaches become more
common in community health centers and other primary care settings. Preliminary results
indicate that more prescribers are becoming waivered, but they would like more mentorship
and support in order to get started and/or treat more patients (Darfler, Urada, and Sandoval,
under review). A recent report (Rowan, 2019) indicates that buprenorphine prescriptions in
California have increased nearly four-fold from 2014-2018, while methadone prescriptions
have remained stable, yet still prescribed at much higher levels than buprenorphine.
According to these data, access to treatment is expanding for OUD.
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The implementation plan for H&S has been responsive to the needs of the network, as topics
and requests arise especially during Learning Collaboratives, where hub and spoke staff
problem-solve challenges and generate solutions to issues that arise when implementing
MOUD in their programs. The questions of how to address pain in someone taking a partial
or full agonist medication for opioid use disorder and how to address treatment in pregnant
women both arose multiple times across regions and training events as important topics
requiring more training. Providers benefit from the opportunity to interact with one and
other, ask questions to more experienced colleagues, and learn from their peers. Another
area that has continued to arise as an important topic is stigma. Even after many trainings
and discussions of stigma, people working in the treatment community and health care
system still believe that taking medications for opioid use disorder is “substituting one drug
for another,” and “patients should be tapered from medication as soon as possible.”
Trainings will continue to emphasize empirically-supported best treatment practices, address
addiction as a chronic disease (McLellan et al., 2000) and use person-first, non-stigmatizing
language (Ashford et al, 2018) when speaking about substance use disorders.

Author Manuscript
Author Manuscript

As the H&S project continues, implementation support and technical assistance will focus
on the needs of the spokes. Feedback from stakeholders and survey data suggest technical
assistance will focus on these areas: continue to support new prescribers with mentoring by
expert facilitators and case consultation on Project ECHO; develop and refine systems to
increase sustainability, e.g., with the nurse care model (LaBelle, Han, Bergeron, and Samet,
2016) that maximizes the effectiveness of the multidisciplinary team and more coordinated
systems of care; educate more pharmacists about buprenorphine to remove pharmacy
barriers to patient access to medications; provide more training on treating comorbid
psychiatric disorders, so mental health clinicians and treatment systems can better address
the complex mental health needs of people with OUD.
The H&S model is increasing access to MOUD across California, with a comprehensive
implementation plan to support prescribers, treatment teams, and health care settings create
the changes needed to save lives in their communities. Further evaluation (Darfler, Urada,
and Sandoval, under review) will determine the overall impact over time.
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H&S

Hub and Spoke

OBOT

Office Based Opioid Treatment

OTP

Opioid Treatment Program

MOUD

Medications for Opioid Use Disorders

MAT

Medication Assisted Treatment

UCLA
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Highlights
•

California’s Hub and Spoke model increases access to opioid use disorder
treatment

•

Prescribers and treatment teams receive implementation support

•

Activities focus on increasing number and skills of prescribers and teams

•

Training and technical assistance include in person and distance learning

Author Manuscript
Author Manuscript
Author Manuscript
J Subst Abuse Treat. Author manuscript; available in PMC 2021 January 01.

Miele et al.

Page 15

Author Manuscript
Author Manuscript
Author Manuscript
Figure 1.

Map of California’s Hub and Spoke system, by region
Map illustrates the geographic reach of the California Hub and Spoke system. Shading
represents the six regions. Stars represent the 18 Hubs and dots represent spoke locations.
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